Detalle Publicación

Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma

Autores: Puig, N. (Autor de correspondencia); Flores-Montero, J.; Burgos Rodríguez, Leire; Cedena, M. T.; Cordon, L.; Perez, J. J.; Sanoja-Flores, L.; Manrique Sáenz de Tejada, Irene; Rodríguez Otero, Paula; Rosinol, L.; Martinez-Lopez, J.; Mateos, M. V.; Lahuerta, J. J.; Blade, J.; San Miguel Izquierdo, Jesús; Orfao, A.; Paiva, B.
Título de la revista: CANCERS
ISSN: 2072-6694
Volumen: 13
Número: 19
Páginas: 4924
Fecha de publicación: 2021
Although the majority of patients with myeloma who achieve undetectable minimal residual disease show prolonged survival, some of them relapse shortly afterwards. False-negative results due to hemodiluted bone marrow samples could explain this inconsistency, but there is no guidance on how to evaluate them. We analyzed three cell populations normally absent in peripheral blood in 1404 aspirates obtained in numerous disease settings and in 85 healthy adults. Pairwise comparisons according to age and treatment showed significant variability, thus suggesting that hemodilution should be preferably evaluated with references obtained after receiving identical regimens. Leveraging the minimal residual disease results from 118 patients, we showed that a comparison with age-matched healthy adults could also inform on potential hemodilution. Our study supports the routine assessment of bone marrow cellularity to evaluate hemodilution, using as reference values either treatment-specific or from healthy adults if the former are unavailable.